When the Carba NP test was used, the color of the wells turned from red to orange or yellow (Figure 1) for all tested strains that were producing carbapenemases (Table 1), whereas wells corresponding to bacterial extracts of isolates that did not produce carbapenemase remained red, whatever their level of carbapenem susceptibility (Table 2).
The Carba NP test perfectly differentiates carbapenemase producers (Table 1) from strains that are carbapenem resistant due to non-carbapenemase-mediated mechanisms, such as combined mechanisms of resistance (outer-membrane permeability defect associated with overproduction of cephalosporinase and/or extended-spectrum P-lactamases) or from strains that are carbapenem susceptible but express a broad-spectrum [beta]-lactamase without carbapenemase activity (extended-spectrum [beta]-lactamase, plasmid and chromosome-encoded cephalosporinases) (Table 2).
The ADF, DF-GLS and NP test
the null of unit root whereas the KPSS tests the null of stationarity.
The NP test
results may be factored into deciding on return to play, although it has not been conclusively demonstrated that NP testing, used in isolation, is an appropriate way to decide when an athlete is safe to return to competition.
Mullin has extensive knowledge of capital markets, both public and private, including a $175 million IPO for NP Test
, a $160 million secondary equity offering of SMART Modular Technologies, Inc.
supplies structural and functional testers.
With regard to outsourcing, Michel Villemain, vice president and general manager of Probe Systems for NP Test
, a subsidiary of Schlumberger, recently said, "The move to overseas outsourcing as a viable way of controlling design and operational costs is growing rapidly.
The company's test and load boards support platforms from all the leading ATE companies such as Agilent, NP test
, Teradyne, Advantest, and Credence, as well as many of the smaller ATE companies.
In CHARTER participants with incidental or contributing conditions, the researchers vised standard NP tests
to determine whether they had asymptomatic neurocognitive impairment (impairment that did not interfere significantly with everyday functioning), mild neurocognitive disorder, or HIV-associated dementia.
are routinely performed in the central laboratory.
On the basis of this evidence, it can only be concluded that a) VCS abnormalities are so widespread and nonspecific as to have limited usefulness as a biomarker for any particular condition (especially in the absence of industrial hygiene or environmental documentation regarding the source of exposure); and b) there is no evidence that VCS deficits have been observed in persons with current active PEAS verified by accepted, objective NP tests
In order to achieve these real-world conditions, TERAGO is leveraging the deep functionality of Spirent's AX/4000 platform, which helped them establish a complete suite of 10 Gigabit NP tests